CLINICAL_TRIALS
ClinicalTrials.gov record update
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05310305
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:43.230821+00:00
- Published At
- 2022-04-11T00:00:00+00:00
- Record Updated At
- 2022-04-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Immune Checkpoint Inhibitors", "Anti-programmed Death-1 Antibody", "Radiotherapy", "Recurrent Cervical Carcinoma", "Metastatic Cervical Carcinoma", "Persistent Advanced Cervical Carcinoma", "Objective Remission Rate", "Progression-free Survival", "Overall Survival", "Severe Adverse Events"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-04-11"- protocolSection.identificationModule.nctId
"NCT05310305"- protocolSection.identificationModule.officialTitle
"Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.